Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of approximately $5.9 billion, has been making waves in the pharmaceutical industry with its flagship drug Rezdiffra ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

The US regulator has cleared Madrigal’s oral THR β-selective agonist Rezdiffra (resmetirom) for adults with MASH – also known as non-alcoholic steatohepatitis (NASH) – who have moderate to ...

James M. Daly currently works at ACADIA Pharmaceuticals, Inc., as Independent Director from 2016, argenx SE, as Independent Non-Executive Director from 2018, and Madrigal Pharmaceuticals ...

During the late ’90s and through the first decade of the 2000s, Cullis, his colleagues at Inex Pharmaceuticals, and the Inex spin-off Protiva Biotherapeutics developed ionizable lipids that are ...

Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

So, when the insiders star Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...